欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的建立体外筛选分析的方法来确定临床所用治疗阿尔茨海默病、帕金森综合症以及骨质疏松症的中药中哪种中药以及哪些成分是与铁离子（Fe3＋）络合的主要成分，并评估其络合强度。方法基于Fe3＋对螺环罗丹明B酰肼衍生物开环显色反应的催化作用，建立了催化光度法测定中药煎液中游离态Fe3＋的方法，进而通过加入一定量Fe3＋测定被络合的程度来评估中药成分与铁络合的强度。结果补肾中药对Fe3＋的络合率较高；采用催化光度法测定中药煎液中游离Fe抖的量，线性范围1．68～22．4mg／L，r=0．9990；平均加标回收率在90．45％～104．11％，RSD〈5％。结论该方法可应用于评估中药络合游离Fe3＋强度。
英文摘要：
Objective To establish the in vitro screening method for determining what kinds of Chinese materia medica （CMM） and which main constituents in the medicine used for the treatment of Alzheimer＇s disease, Parkinson＇s disease, and osteoporosis can chelate with free iron ions （Fe3＋） and evaluating the chelating strength. Methods Based on the catalytic effect of Fe3＋ on the spirolactam （nonfluorescence） to ring-open amide reaction （fluorescence）, the catalytic spectrophotometric method was established to determine the free Fe3＋ in the decoction of CMM, by adding a certain amount of iron ion and determinig the chelating level to evaluate the chelating strength of the constituents in CMM. Results The chelating strength ofkidney-tonifying CMM is stronger. The catalytic spectrophotometric method could be used to determine the free Fe3＋ in the decoction of CMM and the linearity was good in the range of 1.68--22.4 mg/L, r = 0.999 0. The average recovery was between 90.45% and 104.11% with RSD 〈 5%. Conclusion This method can be used to evaluate the chelating capacity of constituents in CMM with Fe3＋.
同期刊论文项目
同项目期刊论文
期刊信息
位置：